Changes in the Etiology of Chronic Liver Disease by Referral to a Fibroscan Center: Rising Prevalence of the Non-Alcoholic Fatty Liver Disease

Background and Aim Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with wide etiological spectrum. FibroScan is used for follow-up of fibrosis and steatosis. This single center study aims to review the distribution of indications by referral to FibroScan.

Materials and Methods Demographic characteristics, CLD etiologies, and FibroScan parameters of the patients, who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.

Results Out of 9,345 patients, 4,946 (52.9%) were male, and median age was 48 [18-88]. Non-alcoholic fatty liver disease (NAFLD) was the most common indication (N=4,768, 51.02%) followed by hepatitis B (N=3,194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, CLD etiology, the results revealed that patients with older age (OR=2.908, CI: 2.597-3.256, P<0.001), and patients with hepatitis C (OR=2.582; CI=2.168-3.075; P<0.001, ALD OR=2.019; CI=1.524-2.674, P<0.001), AIH (OR=2.138; CI=1.360-3.660, P<0.001) had increased odds of advanced liver fibrosis compared to NAFLD.

Conclusion NAFLD was the most common indication for referral to FibroScan. Further studies are warranted to explore the etiological spectrum of CLD in Turkey. TASL

Publikationsverlauf

Artikel online veröffentlicht:
18. Januar 2023